Hematopoietic cell transplantation (HCT) for acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) in children and adolescents - UpToDate
uptodate.com · 433 words · saved by 1 readers
{{configCtrl2.info.metaDescription}}
Hematopoietic cell transplantation for acute myeloid leukemia and myelodysplastic syndromes in children and adolescents INTRODUCTION Allogeneic hematopoietic cell transplantation (HCT) can cure acute myeloid leukemia (AML) and myelodysplastic syndromes/neoplasms (MDS) in children, but it is associated with substantial toxicity and possible transplant-related mortality (TRM). The transplanted hematopoietic cells may recognize the recipient's cells as "foreign" and cause graft-versus-host disease (GVHD), which is a major cause of morbidity and mortality associated with allogeneic HCT.…
saved by
related reading
- Notionnotion.so
- Notionnotion.so
- Acute myeloid leukemia: Children and adolescentsuptodate.com
- Acute myeloid leukemia: Children and adolescentsuptodate.com
- Notionnotion.so
- Immunotherapy in pediatric malignancies: current status and future perspectives - PMCncbi.nlm.nih.gov
- 癌症治療的海豹特種部隊 淺談CAR-T細胞治療法::台灣癌症基金會canceraway.org.tw
- Guidance for Industryfda.gov
- Clinical manifestations, pathologic features, and diagnosis of acute promyelocytic leukemia in adultsuptodate.com
- Initial treatment of acute promyelocytic leukemia in adultsuptodate.com
- Predictors of outcomes in adults with acute myeloid leukemia and KMT2A rearrangementsnature.com
- Childhood leukemia: how a deadly cancer became treatableourworldindata.org